Who is sponsoring NCT04073589?

NCT04073589 is sponsored by argenx.

What condition does NCT04073589 study?

NCT04073589 studies Healthy Volunteers.

What drugs are being tested in NCT04073589?

Interventions: ARGX-113 with rHuPH20.

What is the status of NCT04073589?

NCT04073589 is currently COMPLETED.

Last reviewed 2019-12-30 · How we verify

Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

NCT04073589 PHASE1 COMPLETED

The aim of this trial is to investigate the pharmacodynamic (PD), pharmacokinetic (PK), safety, tolerability, and immunogenicity of efgartigimod co-administered with rHuPH20, and to measure the time to inject the full dose of investigational medicinal product (IMP) of different dose levels of efgartigimod co-administered with a fixed concentration of rHuPH20 by the subcutaneous (SC) route of administration in healthy adult male subjects.

Details

Lead sponsor	argenx
Phase	PHASE1
Status	COMPLETED
Enrolment	33
Start date	Wed Jul 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Sep 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Healthy Volunteers

Interventions

ARGX-113 with rHuPH20

Countries

Netherlands